IL6 and COVID-19: Previous studies (13–15) analyzing serum and CSF inflammatory markers in COVID-19 patients with neurologic manifestations have shown contradictory results, although most studies reported increased levels of IL-6 in serum and CSF (16), which has been used to justify, in part, the use of tocilizumab in those COVID-19 patients with a more severe inflammatory response.